Search

The biotechnology company Mikrobiomik has begun patient recruitment for LiverGut, the first clinical trial in Europe to evaluate an oral therapy based on gut microbiota aimed at slowing the

Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital increase, €7.0 M from commercial bank loans, €13.2 M from the EU-IPCEI grant, and €1

Inveready completes its third venture capital fund with a 4.3x return on capital invested by shareholders

Mikrobiomik launches a Capital Cell funding campaign to support its next clinical trial

The European Health Data Space (EHDS) is conceived as a federated, interoperable, secure and privacy-focused infrastructure, integrating health data generated in all Member States.

A study led by Dr. Iñaki Comino-Méndez and Dr. Emilio Alba from the Hospital Universitario Virgen de la Victoria of Málaga/IBIMA and Dr. Ángel Guerrero-Zotano from the Instituto Valencia de Oncología

Meet our new member, Genomcore. We spoke with Miquel A. Bru, Cofounder & CBDO.

Located in the heart of biomedical innovation in Madrid, and with an investment of over 35 million euros and 18,000 m² of space dedicated to health research as well as scientific, social, and outreach

Meet our new member, BioDuro. We spoke with Ricardo Inacio, Executive Director | Business Development EU.

At AseBio, we strongly support the proposals put forward by the Minister of Industry and Tourism, which not only reflect the work and demands we have been advocating for, but also respond to many of

New U.S. investment bank joins, bringing total coverage to ten analysts.

It aims to turn health data into a strategic asset to improve healthcare, accelerate innovation in health technologies and empower European patients.

AseBio has played a leading role as the head of Work Package 3, “Testing and Implementation,” one of the core pillars of the project.

Meet Maieutics Research Solutions, our new member. We talk with Lander Ezequiel Senderowicz, Operational Manager

New “Decision to grant” communications in Canada and Israel. For the treatment of aggression and social withdrawal